Table 3. Correlation of AKIP1, CXCL1 and CXCL2 expressions with clinical characteristics of patients.
| Items | Total patients, n (%) | AKIP1 expression, n (%) | CXCL1 expression, n (%) | CXCL2 expression, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | P value | High | Low | P value | High | Low | P value | ||||
| No. of patients | 150 | 109 | 41 | 93 | 57 | 77 | 73 | |||||
| Age (years) | 0.326 | 0.258 | 0.505 | |||||||||
| <45 | 72 (48.0) | 55 (76.4) | 17 (23.6) | 48 (66.7) | 24 (33.3) | 39 (54.2) | 33 (45.8) | |||||
| ≥45 | 78 (52.0) | 54 (69.2) | 24 (30.8) | 45 (57.7) | 33 (42.3) | 38 (48.7) | 40 (51.3) | |||||
| HPV status | 0.233 | 0.621 | 0.566 | |||||||||
| Negative | 21 (14.0) | 13 (61.9) | 8 (38.1) | 12 (57.1) | 9 (42.9) | 12 (57.1) | 9 (42.9) | |||||
| Positive | 129 (86.0) | 96 (74.4) | 33 (25.6) | 81 (62.8) | 48 (37.2) | 65 (50.4) | 64 (49.6) | |||||
| Histological type | 0.622 | 0.947 | 0.805 | |||||||||
| SCC | 111 (74.0) | 80 (72.1) | 31 (27.9) | 68 (61.3) | 43 (38.7) | 56 (50.5) | 55 (49.5) | |||||
| ADC | 31 (20.7) | 22 (71.0) | 9 (29.0) | 20 (64.5) | 11 (35.5) | 16 (51.6) | 15 (48.4) | |||||
| ASC | 8 (5.3) | 7 (87.5) | 1 (12.5) | 5 (62.5) | 3 (37.5) | 5 (62.5) | 3 (37.5) | |||||
| Tumor size (cm) | 0.040 | 0.048 | 0.492 | |||||||||
| <4 | 82 (54.7) | 54 (65.9) | 28 (34.1) | 45 (54.9) | 37 (45.1) | 40 (48.8) | 42 (51.2) | |||||
| ≥4 | 68 (45.3) | 55 (80.9) | 13 (19.1) | 48 (70.6) | 20 (29.4) | 37 (54.4) | 31 (45.6) | |||||
| Pathological grade* | 0.359 | 0.627 | 0.062 | |||||||||
| G1 | 43 (28.7) | 31 (72.1) | 12 (27.9) | 25 (58.1) | 18 (41.9) | 28 (65.1) | 15 (34.9) | |||||
| G2 | 58 (38.7) | 39 (67.2) | 19 (32.8) | 35 (60.3) | 23 (39.7) | 24 (41.4) | 34 (58.6) | |||||
| G3 | 49 (32.7) | 39 (79.6) | 10 (20.4) | 33 (67.3) | 16 (32.7) | 25 (51.0) | 24 (49.0) | |||||
| LYN metastasis | 0.034 | 0.948 | 0.026 | |||||||||
| No | 118 (78.7) | 81 (68.6) | 37 (31.4) | 73 (61.9) | 45 (38.1) | 55 (46.6) | 63 (53.4) | |||||
| Yes | 32 (21.3) | 28 (87.5) | 4 (12.5) | 20 (62.5) | 12 (37.5) | 22 (68.8) | 10 (31.3) | |||||
| FIGO stage | 0.021 | 0.316 | 0.123 | |||||||||
| I | 87 (58.0) | 57 (65.5) | 30 (34.5) | 51 (58.6) | 36 (41.4) | 40 (46.0) | 47 (54.0) | |||||
| II | 63 (42.0) | 52 (82.5) | 11 (17.5) | 42 (66.7) | 21 (33.3) | 37 (58.7) | 26 (41.3) | |||||
Correlation was determined by Chi-square test. *, G1, well differentiation; G2, moderate differentiation; G3, poor differentiation. AKIP1, A-kinase interacting protein 1; CXCL1, chemokine (C-X-C motif) ligand 1; CXCL2, chemokine (C-X-C motif) ligand 2; HPV, human papillomavirus; SCC, squamous cell carcinoma; ADC, adenocarcinoma; ASC, adeno squamous carcinoma; LYN, lymph node; FIGO, International Federation of Gynecology and Obstetrics.